Katrien Vandemeulebroecke

Katrien Vandemeulebroecke

Auto-generated profile, based on publicly available information

Katrien Vandemeulebroecke

Cancer Research Institute Ghent (CRIG), Ghent, Belgium; Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium; Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2024 in Cancer Letters
Verified
Journal Article
Open access
Maaike Van TrimpontMaaike Van Trimpont
Maaike Van Trimpont
ASAmanda M. Schalk
Amanda M. Schalk
KHKenneth Hofkens
Kenneth Hofkens
EPEvelien Peeters
Evelien Peeters
STSara T'SAs
Sara T'SAs
ALArnon Lavie
Arnon Lavie
L-asparaginase (L-ASNase) is crucial in treating pediatric acute lymphoblastic leukemia (ALL), but its use is hampered by side effects from the immunogenicity and L-glutaminase (L-GLNase) co-activity of FDA-approved bacterial L-ASNases, often leading to treatment discontinuation and poor outcomes. The toxicity of these L-ASNases makes them especially challenging to use in adult cancer patients. To overcome these issues, we developed EBD-200, a humanized guinea pig L-ASNase with low Km and no L-GLNase activity, eliminating glutamine-related toxicity. EBD-200 showed comparable anti-cancer effects to PEGylated L-ASNase in ASNSlow ALL, melanoma and liver cancer models, with improved tolerability. Its potent anti-cancer efficacy and enhanced safety profile suggest that EBD-200 could benefit ALL patients and broaden treatment options for ASNSlow solid cancers.

25 July 2022 in Pediatric Hematology and Oncology
Verified
Journal Article
Closed access
CDCharlotte Derpoorter
Charlotte Derpoorter
RPRuben Van Paemel
Ruben Van Paemel
KVKatrien Vandemeulebroecke
Katrien Vandemeulebroecke
JVJolien Vanhooren
Jolien Vanhooren
BWBram De Wilde
Bram De Wilde
TLTim Lammens
Tim Lammens
Survival rates for pediatric cancer have significantly increased the past decades, now exceeding 70–80% for most cancer types. The cause of cancer in children and adolescents remains largely unknown and a genetic susceptibility is considered in up to 10% of the cases, but most likely this is an underestimation. Families with multiple pediatric cancer patients are rare and strongly suggestive for an underlying predisposition to cancer. The absence of identifiable mutations in known cancer predisposing genes in such families could indicate undiscovered heritability. To discover candidate susceptibility variants, whole genome sequencing was performed on germline DNA of a family with two children affected by Burkitt lymphoma. Using an inheritance-based filtering approach, 18 correctly segregating coding variants were prioritized without a biased focus on specific genes or variants. Two variants in FAT4 and DCHS2 were highlighted, both involved in the Hippo signaling pathway, which controls tissue growth and stem cell activity. Similarly, a set of nine non-coding variants was prioritized, which might contribute, in differing degrees, to the increased cancer risk within this family. In conclusion, inheritance-based whole genome sequencing in selected families or cases is a valuable approach to prioritize variants and, thus, to further unravel genetic predisposition in childhood cancer.